T‐cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug‐induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well‐known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T‐cell malignancies with nonlethal concentration. Transcription activity of senescence‐suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin‐induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin‐induced aging process. Results showed that wogonin increased the activity of senescence‐associated β‐galactosidase (SA‐β‐Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL‐2 in senescent T‐cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL‐2 inhibitor Navitoclax (ABT‐263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin‐induced senescent cells. Thus, the “one‐two punch” approach increased the sensibility of T‐cell malignancies with low expression of BCL‐2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T‐cell malignancies.
Background: The positive transcription elongation factor b (P-TEFb) kinase activity is involved in the process of transcription. Cyclin-dependent kinase 9 (CDK9), a core component of P-TEFb, regulates the process of transcription elongation, which is associated with differentiation and apoptosis in many cancer types. Wogonin, a natural CDK9 inhibitor isolated fromScutellaria baicalensis.This study aimed to investigate the involved molecular mechanisms of wogonin on anti- chronic myeloid leukemia (CML) cells.Materials and methods: mRNA and protein levels were analysed by RT-qPCR and western blot. Flow cytometry was used to assess cell differentiation and apoptosis. Cell transfection, immunofluorescence analysis and co-immunoprecipitation (co-IP) assays were applied to address the potential regulatory mechanism of wogonin. KU-812 cells xenograftNOD/SCIDmice model was used to assess and verify the mechanism in vivo.Results: We reported that the anti-CML effects in K562, KU-812 and primary CML cells induced by wogonin were regulated by P-TEFb complex. We also confirmed the relationship between CDK9 and erythroid differentiation via knockdown the expression of CDK9. For further study the mechanism of erythroid differentiation induced by wogonin, co-IP experiments were used to demonstrate that wogonin increased the binding between GATA-1 and FOG-1 but decreased the binding between GATA-1 and RUNX1, which were depended on P-TEFb. Also, wogonin induced apoptosis and decreased the mRNA and protein levels of MCL-1 in KU-812 cells, which is the downstream of P-TEFb. In vivo studies showed wogonin had good anti-tumor effects in KU-812 xenograftsNOD/ SCIDmice model and decreased the proportion of human CD45+cells in spleens of mice. We also verified that wogonin exhibited anti-CML effects through modulating P-TEFb activity in vivo.Conclusions: Our study indicated a special mechanism involving the regulation of P-TEFb kinase activity in CML cells, providing evidences for further application of wogonin in CML clinical treatment.
Diffuse large B‐cell lymphoma (DLBCL), a heterogeneous malignancy characterized by distinct genetic and clinical subtypes, remains a therapeutic challenge despite standard R‐CHOP chemotherapy. This study systematically investigated the synergistic anti‐tumor efficacy and mechanism of the histone deacetylase inhibitor chidamide (CHI) combined with doxorubicin (DOX) in DLBCL models. Through multimodal experimental approaches including CCK8 proliferation assays, senescence‐associated β‐galactosidase (SA‐β‐gal) staining analysis, comet assay for DNA damage quantification, and comprehensive western blotting for molecular mechanism elucidation, we identified a potent synergistic interaction between CHI and DOX. By constructing a xenograft tumor model, the synergistic effect of the two drugs and its mechanism in vivo were confirmed. Our research found that CHI showed cell cycle inhibition and apoptosis induction effects on DLBCL cells. When combined with DOX, both synergistically inhibited the proliferation of DLBCL cells and promoted death of DOX‐induced senescent cells. Preliminary mechanism studies revealed that CHI can reduce the level of mutant p53, inhibit cell senescence, and induce irreparable DNA damage in DOX‐induced senescent tumor cells, ultimately leading them into programmed apoptosis. Thus, the “One‐two punch” strategy increased the sensitivity of p53‐mutated DLBCL cells to CHI. In summary, our study demonstrates that CHI synergizes with DOX to suppress DLBCL and presents a promising strategy to augment the therapeutic efficacy of DOX.